soosoo
2021-12-22
Good sharing
S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞的口服COVID-19药丸</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691125672,"tweetId":"691125672","gmtCreate":1640153102058,"gmtModify":1640153102425,"author":{"id":4089777453696550,"idStr":"4089777453696550","authorId":4089777453696550,"authorIdStr":"4089777453696550","name":"soosoo","avatar":"https://static.tigerbbs.com/a7a8e4a0c1e8d4b7bf1e9db91cfaffc8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good sharing</p></body></html>","htmlText":"<html><head></head><body><p>Good sharing</p></body></html>","text":"Good sharing","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691125672","repostId":1188384720,"repostType":4,"repost":{"id":"1188384720","kind":"news","pubTimestamp":1640152952,"share":"https://www.laohu8.com/m/news/1188384720?lang=zh_CN&edition=full","pubTime":"2021-12-22 14:02","market":"us","language":"en","title":"S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞的口服COVID-19药丸</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188384720","media":"Yonhap","summary":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewi","content":"<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.</p><p><blockquote>首尔，12月22日（韩联社）-韩国药品安全局周三表示，已开始审查美国制药巨头辉瑞公司治疗COVID-19的口服药物的紧急授权。</blockquote></p><p> Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.</p><p><blockquote>据辉瑞和食品药品安全部称，Paxlovid是一种抗病毒药物，用于治疗住院或死亡风险增加的轻度至中度COVID-19患者。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5435876a060de363e87a33887064854\" tg-width=\"500\" tg-height=\"324\" width=\"100%\" height=\"auto\"><span>The Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)</span></p><p><blockquote><p class=\"t-img-caption\"><span>食品医药品安全部（照片非卖品）（韩联社）</span></p></blockquote></p><p> If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.</p><p><blockquote>如果获得授权，Paxlovid将成为韩国首个此类口服抗病毒药物。</blockquote></p><p> The drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.</p><p><blockquote>候选药物是一种蛋白酶抑制剂抗病毒疗法，专门设计为口服给药，因此可以在第一次出现感染迹象或第一次意识到暴露时开出处方。</blockquote></p><p> The U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.</p><p><blockquote>美国。据多家媒体报道，美国食品和药物管理局准备本周批准Paxlovid和默克公司的药丸的紧急使用授权。</blockquote></p><p> Pfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.</p><p><blockquote>辉瑞表示，其试验结果显示，Paxlovid可将COVID-19症状出现后三天内重症高危患者的住院或死亡风险降低89%。</blockquote></p><p></p>","source":"lsy1640152899971","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞的口服COVID-19药丸</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS. Korea begins review of Pfizer's oral COVID-19 pill<blockquote>韩国开始审查辉瑞的口服COVID-19药丸</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yonhap</strong><span class=\"h-time small\">2021-12-22 14:02</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.</p><p><blockquote>首尔，12月22日（韩联社）-韩国药品安全局周三表示，已开始审查美国制药巨头辉瑞公司治疗COVID-19的口服药物的紧急授权。</blockquote></p><p> Paxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.</p><p><blockquote>据辉瑞和食品药品安全部称，Paxlovid是一种抗病毒药物，用于治疗住院或死亡风险增加的轻度至中度COVID-19患者。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f5435876a060de363e87a33887064854\" tg-width=\"500\" tg-height=\"324\" width=\"100%\" height=\"auto\"><span>The Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)</span></p><p><blockquote><p class=\"t-img-caption\"><span>食品医药品安全部（照片非卖品）（韩联社）</span></p></blockquote></p><p> If authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.</p><p><blockquote>如果获得授权，Paxlovid将成为韩国首个此类口服抗病毒药物。</blockquote></p><p> The drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.</p><p><blockquote>候选药物是一种蛋白酶抑制剂抗病毒疗法，专门设计为口服给药，因此可以在第一次出现感染迹象或第一次意识到暴露时开出处方。</blockquote></p><p> The U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.</p><p><blockquote>美国。据多家媒体报道，美国食品和药物管理局准备本周批准Paxlovid和默克公司的药丸的紧急使用授权。</blockquote></p><p> Pfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.</p><p><blockquote>辉瑞表示，其试验结果显示，Paxlovid可将COVID-19症状出现后三天内重症高危患者的住院或死亡风险降低89%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://en.yna.co.kr/view/AEN20211222004300320?section=search\">Yonhap</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://en.yna.co.kr/view/AEN20211222004300320?section=search","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188384720","content_text":"SEOUL, Dec. 22 (Yonhap) -- South Korea's drug safety agency said Wednesday that it has begun reviewing an emergency authorization of U.S. drug giant Pfizer Inc.'s oral drug to treat COVID-19.\nPaxlovid is the antiviral pill for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalization or death, according to Pfizer and the Ministry of Food and Drug Safety.\nThe Ministry of Food and Drug Safety (PHOTO NOT FOR SALE) (Yonhap)\nIf authorized, Paxlovid would be the first oral antiviral of its kind in South Korea.\nThe drug candidate is a protease inhibitor antiviral therapy that is specifically designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure.\nThe U.S. Food and Drug Administration is poised to grant an Emergency Use Authorization approval of Paxlovid along with Merck & Co.'s pill this week, according to multiple media reports.\nPfizer said its trial results showed Paxlovid reduces by 89 percent the risk of hospitalization or death in patients at high risk of severe illness within three days of the onset of COVID-19 symptoms.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2441,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691125672"}
精彩评论